BioSpace News Archive

Bristol Myers Squibb Canada (BMS) announced today that Health Canada has approved ONUREG® (azacitidine tablets) for use as the first and only maintenance therapy for adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT)

Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced that Frederick Beddingfield, Chief Executive Officer of Kira Pharmaceuticals, will present at the Virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2021 at 11:35 AM ET.

Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process Hesperidin may help against Covid-19 viral replication Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm

Alexion Highlights Commercial, Clinical and Financial Progress at the 39 th Annual J.P. Morgan Healthcare Conference - Continued advancement of pipeline, including initiation of three Phase 3 development programs and two novel IND filings in Q4 2020 - - Expects to exceed the high end of 2020 revenue guidance, given at Q3 2020 results, of $5.9-$5.95 billion -

Preliminary Unaudited Fourth Quarter 2020 Revenue Expected to be $27.7 to $28.1 Million

PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, announced today that it has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor providing for the purchase and sale of 9,090,910 shares of its common stock

Complementary to STERIS’s product and service portfolio, focused on infection prevention Extends STERIS’s reach to Dental Customers $110 million in expected EBIT synergies by year four Accretive to adjusted earnings per diluted share in year one Conference call with STERIS and Cantel management today at 8:00 a.m. ET

Taking a whole-person approach to health by integrating Cigna medical, pharmacy and behavioral benefits drives better health engagement, outcomes and lowers total health care costs, according to Cigna’s fifth annual Value of Integration study, released

MindMed to Commence Groundbreaking LSD Microdosing Study Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and Immune System Response on the Human Body

The U.S. Food and Drug Administration has granted Emergency Use Authorization (EUA) to one of the first U.S.-manufactured serology tests designed by ADVAITE Inc., an innovative biotech company developing novel point-of-care assays to help with combatting COVID-19